Aims and scope
Announcement
We are pleased to announce that Cellular Oncology will become a fully open access (OA) on 1 January 2025. As a result, all submissions received from 3rd September 2024 are subject to an article publication charge (APC) if accepted and published in the journal (unless a waiver is applied). Please see our FAQs which can be found at the bottom of this page for more information on APCs, funding options, waivers and the journal's transition to fully open access.
Cellular Oncology publishes scientific contributions from various biomedical and clinical disciplines involved in basic and translational cancer research on the cell and tissue level, technical and bioinformatics developments in this area, and clinical applications. This includes a variety of fields like genome technology, micro-arrays and other high-throughput techniques, genomic instability, SNP, DNA methylation, signaling pathways, DNA organization, (sub)microscopic imaging, proteomics, bioinformatics, functional effects of genomics, drug design and development, molecular diagnostics and targeted cancer therapies, genotype-phenotype interactions. A major goal is to translate the latest developments in these fields from the research laboratory into routine patient management. Cellular Oncology forms a platform of scientific information exchange between molecular biologists and geneticists, technical developers, pathologists, (medical) oncologists and other clinicians involved in the management of cancer patients. Cellular Oncology publishes Original Articles, Reviews, Short Communications, Commentaries, and Letters to the Editor.
"In vitro studies are preferentially supported by validations in tumor tissue with clinicopathological associations."